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Background: The survival benefit of a completion axillary lymph node dissection (ALND)
in patients after removal of a metastatic sentinel lymph node (SLN) is uncertain and is under
study in ongoing clinical trials. The completion ALND remains necessary, however, for the
identification of cases with at least four metastatic lymph nodes, in which extended-field
locoregional and/or postmastectomy radiation will be recommended. Our goal was evaluate
clinicopathologic features that might serve as surrogates for determining which patients with a
positive SLN are likely or unlikely to belong to this high-risk subset.
Methods: Records were reviewed for 285 patients from 2 comprehensive cancer centers who
underwent completion ALND after resection of a metastatic SLN from 1995 to 2002. Clini-
copathologic features were analyzed by univariate and multivariate logistic regression. Forty-
one cases (14%) were found to have at least four positive nodes after ALND.
Results: Fishers exact test revealed the following features to be significantly (P < .05)
associated with having four or more nodal metastases: tumor size >2 cm, lymphovascular
invasion, an increasing ratio of positive SLNs to the total number of resected SLNs, ex-
tranodal extension, and the size of the SLN metastasis. Patients whose largest SLN metastasis
was <2 mm had only a 1.4% risk of having four or more metastatic nodes (P < .0001).
Conclusions: We conclude that patients with SLN micrometastases face an extremely low
likelihood of having extensive nodal disease on completion ALND. Patients with larger pri-
mary tumors, lymphovascular invasion, and extranodal extension are more likely to have
ALND findings that will affect their cancer management.
Key Words: Breast cancer—Sentinel lymph node metastases—Axillary lymph node dissec-
tion—Prediction of risk.
The standard level I/II axillary lymph node dis-
section (ALND) has been a routine component of
surgical care for breast cancer patients over the past
century: it provides the prognostically powerful
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definitive proof of axillary node-negative versus
node-positive disease and provides excellent, durable
control of regional disease. The extent to which an
ALND contributes to breast cancer survival, how-
ever, is uncertain. The prognostic and staging benefits
of the ALND must be weighed against its morbidity,
including lymphedema, sensory disturbances, and
shoulder dysfunction.
Intraoperative lymphatic mapping has therefore
rapidly emerged as a primary approach to staging the
axilla, and many institutions have come to accept a
negative sentinel lymph node (SLN) as an accurate
means of identifying the node-negative patient, for
whom the ALND can be safely avoided. A comple-
tion ALND remains the standard of care for a patient
with a metastatic SLN; however, this practice has
been questioned because of studies demonstrating
that axillary metastases are limited to the SLNs in
30% to 50% of cases. Furthermore, historic clinical
trial data suggest that prophylactic resection of occult
axillary metastases is comparable to axillary obser-
vation and delayed therapeutic ALND for cases of
regional failure.1
The American College of Surgeons Oncology
Group attempted to define the value of the ALND
in node-positive breast cancer by randomizing
SLN-positive patients to axillary observation versus
the standard completion axillary operation.2
Unfortunately, this trial was recently closed because
of poor accrual rates.3 The inability to complete
this important trial is likely to strengthen interest in
statistical models that can identify patients likely to
harbor additional metastatic nodes after resection
of at least one metastatic SLN.4,5 The goal of these
prediction tools is to refine the selection of SLN-
positive patients who require the completion
ALND.
Given the uncertainties regarding the survival
benefits associated with the completion ALND, a
valid argument can be made that the critical issue is
to identify the subset of high-risk SLN-positive pa-
tients, as defined by having a total of four or more
metastatic lymph nodes, rather than identifying the
subset of patients with any metastatic non-SLNs. It
is important to accurately identify this subset of
patients because they will be recommended to receive
more extensive locoregional therapy in the form of
postmastectomy radiation or extended-field radiation
after lumpectomy.6,7 Available data suggest that this
category represents 10% to 15% of all clinically early-
stage breast cancer patients with at least one meta-
static SLN.8–11 The goal of this study was to identify
clinicopathologic features that distinguish SLN-po-
sitive patients who are likely to have at least four
metastatic axillary lymph nodes.
MATERIALS AND METHODS
The study population included SLN-positive breast
cancer patients with T1 and T2 tumors (based on
clinical assessment) who underwent completion
ALND at 1 of 2 comprehensive cancer centers: the
University of Michigan (103 cases) and the University
of Texas M. D. Anderson Cancer Center (182 cases)
between the years 1995 and 2002. Patients with four
or more metastatic SLNs, patients who received
neoadjuvant chemotherapy, and patients with insuf-
ficient information available on multiple clinico-
pathologic features were excluded from analysis. The
conduct of these analyses was approved by the Uni-
versity of Michigan Institutional Review Board.
Clinicopathologic features for the study popula-
tion were analyzed after stratification by extent of
total axillary metastatic burden (a total of one to
three positive nodes vs. four or more positive no-
des).The significance of bivariate associations be-
tween patient, tumor, and SLN characteristics was
explored by using the Fishers exact test. Charac-
teristics with P values £5% were considered for
multivariate analysis. Unconditional logistic regres-
sion was used to model the occurrence of a positive
case (having four or more metastatic nodes). For the
computation of predicted probabilities, we chose to
fix the total number of SLNs removed at the value of
three, which is the median number of SLNs identi-
fied and resected. We applied this strategy to
emphasize the contribution of the absolute number
of metastatic SLNs, because the proportion repre-
sented by comparing the number of metastatic SLNs
with the total number of SLNs resected will vary
substantially with differences in the sentinel nodal
drainage pattern and surgical specimen. Odds ratios
and their 95% confidence intervals were reported for
all characteristics found to be significant in the
multivariate model.
RESULTS
Table 1 demonstrates the clinicopathologic fea-
tures of the study populations. Forty-one (14%) of
the 285 evaluated cases were found to have at least 4
positive lymph nodes after completion ALND. The
study population profiles from the two participating
institutions were comparable, with an average age of
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52 years. The median number of SLNs removed was
3, and the median number of non-SLNs resected
with the completion ALND was 16. Approximately
two thirds of the cases from both participating
institutions were T1 cancers, with a median size of
18 mm, and only three patients had T3 tumors
(measuring 52, 60, and 67 mm on final pathologic
analysis).
As shown by the bivariate comparisons presented
in Table 2, factors found to be significantly associ-
ated with having four or more nodal metastases in-
cluded a primary tumor size >2 cm, lymphovascular
invasion, extranodal extension, the size of the SLN
metastasis, and an increasing ratio of positive SLNs
to the total number of resected SLNs. Patient age,
tumor histological characteristics, tumor grade, and
TABLE 1. Patient, tumor, and node characteristics
Characteristic UMCC MDACC Total
No. of cases 103 (36.1%) 182 (63.9%) 285
Age
Median, y (range) 52 (31–78) 52 (29–78) 52 (29–78)
£50, n (%) 46 (44.7) 83 (45.6) 129 (45.3)
>50, n (%) 57 (55.3) 99 (54.4) 156 (54.7)
Tumor histological findings, n (%)
Ductal 80 (77.7) 132 (72.5) 212 (74.4)
Lobular 14 (13.6) 14 (7.7) 28 (9.8)
Ductal and lobular 2 (1.9) 17 (9.3) 19 (6.8)
DCISa 4 (3.9) 2 (1.1) 6 (2.1)
Other 3 (2.9) 17 (9.3) 20 (7.0)
Tumor size (cm), n (%)
£2 69 (67.0) 116 (63.7) 185 (64.9)
>2 32 (31.1) 66 (36.3) 98 (34.4)
Unknown 2 (1.9) 0 2 (.7)
Lymphovascular invasion, n (%)
Present 28 (27.2) 49 (26.9) 77 (27.0)
Absent 73 (70.9) 133 (73.1) 206 (72.3)
Unknown 2 (1.9) 0 2 (.7)
Extranodal extension, n (%)
Present 17 (16.5) 53 (29.1) 70 (24.6)
Absent 78 (75.7) 129 (70.9) 207 (72.6)
Unknown 8 (7.8) 0 8 (2.8)
Tumor grade, n (%)
I 16 (15.5) 15 (8.2) 31 (10.9)
II 60 (58.3) 109 (59.9) 169 (59.3)
III 20 (19.4) 55 (30.2) 75 (26.3)
Other/unknown 7 (6.8) 3 (1.7) 10 (3.5)
Estrogen receptor, n (%)
Positive 78 (75.7) 150 (82.4) 228 (80.0)
Negative 23 (22.3) 31 (17.0) 54 (19.0)
Unknown 2 (1.9) 1 (.6) 3 (1.1)
Total lymph nodes removed, median (range) 18 (6–44) 19 (4–44) 19 (4–44)
Non-SLNs removed, median (range) 15 (5–40) 17 (1–42) 16 (1–42)
SLNs removed
Median (range) 3 (1–15) 2 (1–9) 3 (1–15)
1, n (%) 22 (21.4) 38 (20.9) 60 (21.1)
2, n (%) 24 (23.3) 55 (30.2) 79 (27.7)
3, n (%) 28 (27.2) 42 (23.1) 70 (24.6)
‡4, n (%) 29 (28.2) 47 (25.8) 76 (26.7)
Positive SLNs, n (%)
1 73 (70.9) 125 (68.7) 198 (69.5)
2 25 (24.3) 45 (24.7) 70 (24.6)
3 5 (4.9) 12 (6.6) 17 (6.0)
Size of largest metastatic SLN focus, n (%)
<2 mm or IHC only 38 (36.9) 36 (19.8) 74 (26.0)
‡2 mm 57 (55.3) 137 (75.3) 194 (68.1)
Unknown 8 (7.8) 9 (5.0) 17 (6.0)
Total positive axillary lymph nodes
<4 89 (86.4) 155 (85.2) 244 (85.6)
‡4 14 (13.6) 27 (14.8) 41 (14.4)
UMCC, University of Michigan Comprehensive Cancer Center; MDACC, M. D. Anderson Comprehensive Cancer Center; DCIS, ductal
carcinoma-in-situ; SLN, sentinel lymph node; IHC, immunohistochemically detected.
a Predominantly DCIS histopathological findings but with suspected microinvasion.
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hormone receptor status were not found to be sig-
nificant predictors of an extensive metastatic nodal
burden. The single feature associated with the lowest
risk of having four or more metastatic axillary nodes
was the size of the largest metastatic focus: of 74
patients with SLN micrometastases (tumor focus up
to 2 mm in diameter), only 1 (1.4%) was found to
have high-risk nodal disease. Seventeen patients
(which included four positive cases) in this dataset did
not have any information for the size of their nodal
disease. Not surprisingly, nearly half of patients with
three metastatic SLNs had at least one additional
positive non-SLN, thereby placing them into the
high-risk subset. Only 5% of patients with a single
metastatic SLN were ultimately found to have four or
more positive nodes.
Multivariate analysis was conducted by using the
significant characteristics described previously. Tu-
mor size, lymphovascular invasion, extranodal
extension, the number of positive lymph nodes, and
the ratio of positive SLNs to the total number of
SLNs removed were all found to be independently
TABLE 2. Bivariate associations of patient/tumor/sentinel node characteristics with the extent of nodal metastasis
Characteristic
‡4 metastatic nodes
(n = 41), n (%)
1–3 metastatic nodes




£50 22 (17.1) 107 (82.9) .3090
>50 19 (12.2) 137 (87.8)
Tumor histological findings
Ductal 28 (13.2) 184 (86.8) .5816
Lobular 5 (17.9) 23 (82.1)
Ductal and lobular 4 (21.1) 15 (78.9)
DCIS 0 6 (100)
Other 4 (20.0) 16 (80.0)
Tumor size (cm)
£2 15 (8.1) 170 (91.9) <.0001
>2 25 (25.5) 73 (74.5)
Unknown 1 (50.0) 1 (50.0)
Lymphovascular invasion
Present 21 (27.3) 56 (72.7) <.0001
Absent 20 (9.7) 186 (90.3)
Unknown 0 2 (100)
Extranodal extension
Present 22 (31.4) 48 (68.6) <.0001
Absent 19 (9.2) 188 (90.8)
Unknown 0 8 (100)
Tumor grade
I 1 (3.2) 30 (96.8) .2340
II 26 (15.4) 143 (84.6)
III 13 (17.3) 62 (82.7)
Other/unknown 1 (10.0) 9 (90.0)
Estrogen receptor
Positive 31 (13.6) 197 (86.4) .3457
Negative 9 (16.7) 45 (83.3)
Unknown 1 (33.3) 2 (66.7)
SLNs removed
1 6 (10.0) 54 (90.0) .0079
2 21 (26.6) 58 (73.4)
3 7 (10.0) 63 (90.0)
‡4 7 (9.2) 69 (90.8)
Positive SLNs
1 10 (5.1) 188 (94.9) <.0001
2 23 (32.9) 47 (67.1)
3 8 (47.1) 9 (52.9)
Percentage of positive SLNs (%)
1–25 0 46 (100) <.0001
26–50 8 (6.8) 109 (93.2)
51–75 7 (26.9) 19 (73.1)
76–100 26 (27.1) 70 (72.9)
Size of largest metastatic SLN focus (mm)
<2 or IHC only 1 (1.4) 73 (98.6) <.0001
‡2 36 (18.6) 158 (81.4)
Unknown 4 (23.5) 13 (76.5)
DCIS, ductal carcinoma-in-situ; SLN, sentinel lymph node; IHC, immunohistochemically detected.
PREDICTION OF HIGH-RISK BREAST CANCER CASES 39
Ann. Surg. Oncol. Vol. 13, No. 1, 2006
and significantly related to a final pathologic result of
at least four metastatic nodes (Table 3). The size of
the largest metastatic focus within the positive SLNs
lost statistical significance after adjustment for the
other characteristics in the multivariate analysis.
Tumors >2 cm, lymphovascular invasion, and ex-
tranodal extension were all associated with an
approximately 3-fold increase in the odds of being a
positive case. Having two or three positive SLNs,
when compared with having only a single positive
node, was associated with more than a 4- and 7-fold
increase in the odds of being a positive case in this
sample, respectively. Similarly, the likelihood of
having extensive nodal disease was directly correlated
with the ratio of positive SLNs to the total number of
resected SLNs.
The predicted probabilities of having extensive
nodal disease were calculated on the basis of the
multivariate model in Table 3, and these data are
reported in Table 4. Probabilities were calculated for
a patient with one, two, or three positive SLNs, with
the total number of SLNs fixed at 3, with and without
the other risk factors. For example, Table 4 shows
that a patient with two metastatic SLNs, a T2 or T3
tumor, and extranodal extension, but no lympho-
vascular invasion, has a 41.9% predicted probability
of having high-risk nodal disease. The minimum
predicted probability was an estimate of .2% for cases
of a single metastatic SLN with a T1 breast tumor
that was negative for lymphovascular invasion and
extranodal extension. The highest estimate, of 90%,
was calculated for cases of three metastatic SLNs
associated with a tumor >2 cm and characterized by
both adverse histological patterns. For all cases of a
single metastatic SLN, there was a £5% risk of having
high-risk disease unless the primary tumor was >2
cm and both extranodal extension and lymphovas-
cular invasion were present. With the latter combi-
nation, the risk of having high-risk disease increased
to 15%. All combinations of features that included
three positive SLNs were associated with an at least
25% risk of having four or more metastatic nodes.
DISCUSSION
During the 1970s, the National Surgical Adjuvant
Breast Project B-04 study demonstrated survival
equivalence for operable, clinically node-negative
breast cancer patients managed by axillary surgery
versus axillary irradiation versus observation and
delayed therapeutic ALND at the time of regional
failure. This outcome equivalence has persisted on
25-year follow-up.1 Despite these findings, the
ALND remained an essential component of breast
cancer management because the axillary nodal status
became the most powerful determinant of the mag-
nitude of benefit from adjuvant systemic therapy.
Furthermore, the B-04 study was not powered sta-
tistically to address the survival benefits of the
ALND; it was designed to evaluate the overall safety
of modified surgical strategies (radical mastectomy
vs. total mastectomy vs. total mastectomy and loco-
regional irradiation) as treatment for operable breast
cancer. Accrual to this phase III clinical trial was
completed in an era of surgical treatment alone for
breast cancer management, before the advent of
effective systemic therapy for breast cancer.
A standard level I/II ALND has therefore been
routinely performed in patients with invasive breast
TABLE 3. Multivariate associations of significant patient/tumor/SLN characteristics with high-risk axillary disease




>2 1.17 3.24 1.38–7.61 .0071
Lymphovascular invasion
Absent 0 1
Present 1.05 2.85 1.23–6.62 .0148
Extranodal extension
Absent 0 1
Present 1.08 2.94 1.24–6.96 .0141
Positive SLNs
1 0 1
2 1.47 4.35 1.76–10.75
3 2.03 7.60 2.02–28.61 .0010
Percentage of positive SLNs
Continuous covariate .03 1.03 1.01–1.05 .0001
SLN, sentinel lymph node; OR, odds ratio; CI, confidence interval.
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cancer, but several issues have motivated efforts to
modify this strategy. First, ALND patients face a
lifelong risk of lymphedema that ranges from 10%
to 50%,12 depending on other risk factors, the
duration of follow-up, and the method of detection.
Other morbidities associated with an ALND include
neurosensory disturbances and shoulder dysfunc-
tion.13 Also, the successful implementation of breast
cancer screening programs has resulted in detection
of high proportions of microinvasive and T1a tu-
mors that are more likely to be node negative, but
these patients have nonetheless faced the morbidity
of the ALND to have definitive proof of their node-
negative status.
The introduction of intraoperative lymphatic
mapping and SLN biopsy programs for breast cancer
patients14,15 was followed by the rapid adoption of
this technology to stage newly diagnosed cases.16
Many programs now routinely accept a negative SLN
as accurate, and these patients are spared the mor-
bidity of the completion ALND. Several studies with
long-term follow-up17–20 are now reporting excellent
results with this strategy, as well as improved quality
of life. The SLN biopsy therefore screens newly
diagnosed breast cancer patients for nodal metasta-
ses, and only SLN-positive patients proceed to un-
dergo completion ALND.
Ongoing controversies regarding the survival ben-
efits of the standard ALND in patients with a clini-
cally benign axilla are therefore revisited in the era of
SLN biopsy. Once the presence versus absence of
nodal metastases is confirmed histopathologically
and this information is appropriately incorporated
into decision algorithms for adjuvant systemic ther-
apy, it can be argued that the completion ALND is
unnecessary. As suggested by the National Surgical
Adjuvant Breast Project B-04 study, clinically occult
and untreated axillary metastases will progress into
clinically evident disease that necessitates a delayed
therapeutic ALND in approximately half of cases,
and this outcome does not seem to adversely affect
survival when compared with patients whose axillary
disease was detected by a staging ALND at the time
of diagnosis.1 Overall, 19% of the patients random-
ized to total mastectomy alone experienced an ax-
illary relapse as an initial treatment failure.
The risk of regional failure is likely to be sub-
stantially lower in contemporary practice, where the
node-positive patient is identified by an SLN biopsy.
The standard of care for these patients with stage II
TABLE 4. Multivariate model predictions for the probability of a positive case
Positive SLNsa Tumor size (cm) Lymphovascularinvasion Extranodal extension Predicted probability
1 £2 Absent Absent .002
2 £2 Absent Absent .070
3 £2 Absent Absent .267
1 >2 Absent Absent .020
2 >2 Absent Absent .197
3 >2 Absent Absent .541
1 £2 Present Absent .017
2 £2 Present Absent .177
3 £2 Present Absent .510
1 £2 Absent Present .018
2 £2 Absent Present .182
3 £2 Absent Present .518
1 >2 Present Absent .055
2 >2 Present Absent .411
3 >2 Present Absent .771
1 >2 Absent Present .057
2 >2 Absent Present .419
3 >2 Absent Present .776
1 £2 Present Present .050
2 £2 Present Present .389
3 £2 Present Present .754
1 >2 Present Present .146
2 >2 Present Present .673
3 >2 Present Present .908
SLN, sentinel lymph node.
a The total number of SLNs removed was fixed at 3.
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disease will include adjuvant systemic therapy, which
will contribute to control of regional disease.21 Also,
studies of patients undergoing SLN biopsy with a
concomitant ALND have demonstrated that axillary
metastases will be limited to the SLN in 30% to 67%
of cases.8,15,22–24 In these cases, the completion
ALND subjects the patient to additional surgery and
morbidity to remove negative non-SLNs.
The American College of Surgeons Oncology
Group Z0011 protocol was a prospective, random-
ized trial specifically designed to answer the question
of whether the completion ALND will improve out-
come in SLN-positive patients, by randomizing these
cases to standard axillary surgery versus axillary
observation. The unfortunate recent closure of this
trial because of slow accrual rates (but not because of
adverse event rates, which have thus far been low in
both the ALND and axillary observation arms)
leaves this question unanswered and has strengthened
the need for alternative strategies that can improve
our ability to determine which SLN-positive patients
are likely to benefit from the completion ALND.
Van Zee et al.4 therefore developed a nomogram
that estimates the likelihood that an individual SLN-
positive patient will have additional metastatic nodes
in the completion ALND specimen. Degnim et al.5
conducted a meta-analysis of studies involving SLN
biopsy with concomitant ALND, and this pooled
analysis provided a robust assessment of the clinico-
pathologic features associated with the likelihood of
detecting metastatic disease in non-SLNs. Both of
these investigators have found primary tumor size
and extent of SLN pathology to be strong predictors
of non-SLN disease.
Accurate identification of patients with any meta-
static non-SLNs is a potentially valuable strategy, but
it is most important for the surgeon to identify the
subset of high-risk cases in which adjuvant therapy
(and possibly survival) will be influenced by the
pathology findings from the completion ALND
specimen. Patients with one, two, or three metastatic
lymph nodes will receive ‘‘standard’’ adjuvant sys-
temic therapy for node-positive disease, and adjuvant
radiation will be delivered on the basis of the primary
operation (lumpectomy vs. mastectomy) and primary
tumor size. In contrast, patients with high-risk dis-
ease defined by the presence of four or more meta-
static lymph nodes will be referred for extended-field
irradiation to the chest wall and nodal basins.6,7 As
shown in Table 5, approximately 10% to 16% of
SLN-positive breast cancer patients will fall into this
high-risk category, and these patients clearly benefit
from aggressive surgical and radiotherapeutic ap-
proaches aimed at optimizing locoregional control of
disease. We therefore sought to develop a model
based on the clinicopathologic features studied by
Van Zee et al.4 and Degnim et al.5 to specifically
identify SLN-positive patients with extensive axillary
nodal disease.
Shahar et al.25 addressed this issue as well in their
study from the University of Texas M. D. Anderson
Cancer Center, where the following features were
predictive of having four or more metastatic nodes
after a positive SLN biopsy: no drainage seen on
lymphoscintigraphy, more than one positive SLN,
and lymphovascular space invasion. The M. D.
Anderson study was based on 28 high-risk patients
(10.5%) identified from 265 SLN-positive patients.
We sought to expand on this work by studying a
more robust dataset composed of patients treated at
the M. D. Anderson Cancer Center and the Univer-
sity of Michigan Comprehensive Cancer Center. This
approach yielded 41 cases with at least 4 metastatic
nodes (14% of the total 285-patient population).
Our bivariate comparisons revealed that the size of
the metastatic focus in the SLN was strongly corre-
lated with the risk of having high-risk axillary disease.
Of the 74 patients with micrometastatic disease in the
SLN (focus up to 2 mm in diameter or detected by
immunohistochemistry), only 1 (1.4%) had extensive
nodal disease, versus 36/194 (19%) patients with
metastatic foci >2 mm (P <.0001). This feature was
one of the most powerful predictors identified in the
pooled analysis by Degnim et al.5 as well. Logistic
regression, however, revealed that the size of the
metastatic focus was no longer an independently
predictive variable. The model that we developed was
therefore based on the primary tumor size, the vol-
ume of SLN metastases, and the presence versus
absence of lymphovascular invasion and extranodal
extension. These characteristics retained significance
in our multivariate analysis.
TABLE 5. Proportion of SLN-positive breast cancer
patients found to have at least four metastatic nodes after
SLN biopsy and completion ALND (metastatic SLNs and
non-SLNs)










This study 285 14
SLN, sentinel lymph node; ALND, axillary lymph node dissec-
tion.
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Our multivariate model also indicated that
the percentage of metastatic SLNs (the number of
metastatic SLNs divided by the total number of
SLNs resected multiplied by 100) was significant as a
continuous covariate (odds ratio, 1.03; 95% confi-
dence interval, 1.01–1.05; P = .0001). For the pre-
sentation of predicted probabilities listed in Table 4,
we chose to fix the total number of SLNs removed at
the median value of 3 to focus the readers attention
on the contribution of the absolute number of met-
astatic SLNs. The proportion of metastatic SLNs to
the total number of SLNs resected will vary sub-
stantially with differences in the sentinel nodal
drainage pattern and surgical specimen. If the total
number of SLNs removed was >3, the percentage of
metastatic to total SLNs would be reduced in our
prediction model; hence, the predicted probabilities
listed in Table 4 would be also be reduced. For an
example, if we consider two identical patients, each
with a T1/T2 tumor and without lymphovascular
invasion or extranodal extension, then a patient with
only a single SLN removed that is also metastatic will
have a percentage of 100%, whereas a patient with
only 1 metastatic node out of a total of 10 SLNs
resected will have a percentage of only 10%. The
predicted probability of having high-risk axillary
disease is 4.6% for the former example and only .3%
for the latter. This difference illustrates that by
including the percentage of metastatic SLNs in our
final multivariate model, we are correctly accounting
for the extent of axillary sampling that has been
achieved by the sentinel lymphadenectomy. Intui-
tively, a larger extent of the sentinel drainage area,
the involved nodes, and the resultant sentinel lym-
phadenectomy, without the discovery of four or more
metastatic nodes, reduces the number of nodes
remaining in the axilla that could be harboring met-
astatic disease, thus reducing a patients probability
of having extensive axillary disease.
In summary, our study of SLN-positive breast
cancer yielded a straightforward and biologically
plausible strategy for assessing the risk that a patient
will be found to have a total metastatic burden of
four or more involved lymph nodes. Our model re-
vealed a .2% likelihood that a completion ALND
will convert a case with a T1 tumor and a single
positive SLN that lacks both lymphovascular inva-
sion and extranodal extension into a case of exten-
sive nodal disease. The likelihood of having high-
risk pathologic characteristics identified on comple-
tion ALND can be estimated by evaluating the
primary tumor size, volume of metastatic SLNs, and
presence versus absence of adverse histopathologic
features. A completion ALND remains the standard
of care for patients who have a metastatic SLN, but
the ability to predict the likelihood that this ALND
will affect subsequent management can be helpful in
cases in which the patient or the multidisciplinary
oncology team is reluctant pursue additional sur-
gery. Our results require validation by other inves-
tigators.
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